AMAG Pharmaceuticals (AMAG Pharmaceuticals) GF Score : 0/100 (As of May. 05, 2024)

View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals GF Score?

AMAG Pharmaceuticals has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes AMAG Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

AMAG Pharmaceuticals (NAS:AMAG) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

AMAG Pharmaceuticals GF Score Related Terms

Thank you for viewing the detailed overview of AMAG Pharmaceuticals's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Winter Street, Waltham, MA, USA, 02451

Website

https://www.amagpharma.com

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.

Executives

Camber Capital Management Lp	10 percent owner	101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano	officer: Chief Operating Officer	C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos	officer: Interim CFO	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson	director, 10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat	director
Davey Scoon	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers	director, officer: President & CEO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick	officer: Chief Human Resources Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022